ASCO 2019: A new potential de-escalation standard neoadjuvant treatment of HER2-positive breast cancer

Theodoros Foukakis | ASCO 2019 | Juni 6, 2019

Föreläsare: Theodoros Foukakis

In this randomized phase II study patients ≥18 years with HER2 positive breast cancer > 20mm or verified lymph node metastases were randomized to 6 courses of docetaxel, trastuzumab and pertuzumab (DTP, group A) or trastuzumab emtansine (T-DM1, group B), q 21 days. 

 

In this MEDtalk Theodoros Foukakis explain, why data on treatment with trastuzumab emtansine demonstrates similar efficacy and less toxicity, in particular for patients with HER2 and HR positive cancers, being a potential new standard for neoadjuvant therapy.